Farxiga vs Tresiba: Side-Effect Profile Head-to-Head

Two Drugs, Two Mechanisms, Two Risk Profiles

Farxiga blocks the SGLT2 cotransporter in the proximal tubule of the kidney, forcing excess glucose into the urine. Tresiba supplies exogenous insulin through a depot of multi-hexamer chains that dissolve over 42+ hours. These mechanisms share almost nothing in common, and neither do the adverse events they produce.

Dapagliflozin's glucose-lowering action is insulin-independent, which means hypoglycemia is uncommon when the drug is used without sulfonylureas or insulin 1. Insulin degludec, by contrast, lowers glucose by direct receptor activation and carries an inherent hypoglycemia risk that scales with dose. The 2017 DEVOTE trial (N=7,637) established that degludec produced 40% fewer episodes of severe nocturnal hypoglycemia compared to insulin glargine U100 (rate ratio 0.47, 95% CI 0.31 to 0.73) 2. That difference mattered clinically: nocturnal events are the hypoglycemia subtype most associated with cardiac arrhythmia and patient anxiety.

Because no randomized controlled trial has ever compared dapagliflozin directly to insulin degludec, every comparison here is cross-trial. Interpret the data with that limitation in mind.

Hypoglycemia: The Defining Difference

Hypoglycemia risk separates these drugs more than any other safety signal. Farxiga monotherapy rarely causes blood glucose to drop below 70 mg/dL because the kidney simply stops excreting glucose once plasma levels fall to the renal threshold 3. In phase III pooled data, the incidence of major hypoglycemia with dapagliflozin monotherapy was 0.1%, comparable to placebo.

Tresiba's story is different. As a basal insulin, hypoglycemia is the most predictable adverse event. DEVOTE documented severe hypoglycemia in 4.9% of the degludec arm over the median 1.99-year follow-up 2. The advantage Tresiba holds over older basal insulins is its ultra-flat pharmacokinetic profile. The coefficient of variation in glucose-lowering effect is four times lower than that of glargine U100, which translates to fewer glucose excursions at both ends of the spectrum.

For patients on combination regimens, the picture shifts. Adding Farxiga to insulin therapy does increase hypoglycemia incidence (the prescribing information recommends reducing the insulin dose when initiating dapagliflozin) 3. Still, the mechanism of hypoglycemia in that pairing is driven by the insulin, not the SGLT2 inhibitor.

Genital Mycotic Infections and Urinary Tract Concerns

This side-effect category belongs almost exclusively to Farxiga. Glycosuria creates a high-glucose environment in the genitourinary tract, and Candida species thrive in it. In clinical trials, genital mycotic infections occurred in 4.8% of women and 2.8% of men taking dapagliflozin 10 mg, compared to 0.9% and 0.3% on placebo 3.

Most episodes are mild. They respond to a single course of topical or oral antifungal therapy. Recurrence rates drop after the first six months of treatment in observational follow-up data. The FDA label also notes a small signal for urinary tract infections (UTIs), though the absolute difference versus placebo is modest (5.7% vs 4.3% for women). The American Diabetes Association's 2024 Standards of Care notes that SGLT2 inhibitor-related UTIs "are generally uncomplicated and respond to standard antimicrobial treatment" 4.

Tresiba does not increase infection risk at any site. Injection-site reactions (lipodystrophy, localized amyloidosis with prolonged use at the same site) are the closest anatomical-site adverse event, and they occur in <2% of patients with proper rotation technique 5.

Diabetic Ketoacidosis: A Low-Frequency, High-Severity Signal

Euglycemic DKA (euDKA) is the side effect that generates the most clinical caution around SGLT2 inhibitors. Farxiga carries an FDA boxed-warning-adjacent class label noting this risk. The mechanism involves increased lipolysis and ketogenesis driven by SGLT2 inhibition in the setting of relative insulin deficiency. Blood glucose may remain below 250 mg/dL, which delays recognition.

In the DAPA-HF trial (N=4,744), DKA events were rare: 3 cases in the dapagliflozin group versus 0 in placebo over a median 18.2 months 1. Real-world pharmacovigilance data from the FDA Adverse Event Reporting System suggest a class-wide SGLT2 inhibitor DKA incidence of roughly 0.1% per patient-year 6. Triggers include surgery, prolonged fasting, acute illness, and inadvertent use in patients with latent autoimmune diabetes.

Tresiba, as an insulin product, does not cause DKA. It treats DKA. This is a clear-cut safety differentiator for patients with a history of ketosis-prone diabetes or those planning elective surgery.

Weight and Metabolic Effects

Body weight trends in opposite directions with these two drugs. A fact that matters to patients and affects adherence.

Dapagliflozin consistently produces 2 to 3 kg of weight loss over 24 to 52 weeks in type 2 diabetes trials. The DECLARE-TIMI 58 trial (N=17,160) confirmed sustained weight reduction of approximately 1.8 kg at 48 months versus placebo 7. This effect is caloric: roughly 60 to 80 grams of glucose (240 to 320 kcal) are excreted in urine per day at therapeutic doses.

Insulin degludec, like all exogenous insulins, promotes anabolism. In DEVOTE, the mean weight gain in the degludec arm was modest (approximately 1 kg over 2 years), though individual variation was wide 2. Higher doses correlate with more weight gain. For patients already struggling with obesity (which describes the majority of the type 2 diabetes population), this directional difference can influence treatment satisfaction and long-term glycemic durability.

The 2024 ADA Standards of Care state: "When choosing among glucose-lowering therapies, clinicians should consider the effect on body weight, particularly for patients with overweight or obesity" 4. This recommendation effectively favors SGLT2 inhibitors and GLP-1 RAs over insulin when glycemic targets can be met without basal insulin.

Cardiovascular and Renal Outcomes

Both drugs have completed large cardiovascular outcome trials (CVOTs), but the results tell very different stories.

DAPA-HF randomized 4,744 patients with heart failure and reduced ejection fraction (HFrEF) to dapagliflozin 10 mg or placebo. The primary composite endpoint (worsening HF or cardiovascular death) occurred in 16.3% of the dapagliflozin group versus 21.2% on placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) 1. That 26% relative risk reduction earned dapagliflozin an FDA indication for HFrEF regardless of diabetes status. The DAPA-CKD trial subsequently extended the renal-protective indication to chronic kidney disease with eGFR 25 to 75 mL/min 8.

DEVOTE (N=7,637) was designed as a non-inferiority CVOT comparing insulin degludec to insulin glargine U100. The primary outcome (three-point MACE: CV death, nonfatal MI, nonfatal stroke) occurred in 8.5% of the degludec group and 9.3% of the glargine group (HR 0.91, 95% CI 0.78 to 1.06), confirming non-inferiority 2. Tresiba did not demonstrate cardiovascular superiority. Dr. Steven Marso, the lead DEVOTE investigator, noted at the time of publication: "Degludec is at least as safe as glargine from a cardiovascular standpoint, with the added benefit of significantly less hypoglycemia."

The practical implication: for a patient with established heart failure or chronic kidney disease, dapagliflozin offers organ-protective benefits that insulin degludec does not. For a patient who needs exogenous insulin to control hyperglycemia (typically those with significant beta-cell failure), Tresiba remains appropriate, and its CV safety is confirmed.

Volume Depletion and Blood Pressure Effects

Farxiga's osmotic diuretic action removes approximately 200 to 400 mL of extra fluid per day. This produces a mean systolic blood pressure reduction of 3 to 5 mmHg 3. For most patients with type 2 diabetes and concomitant hypertension, this is a welcome secondary effect. For elderly patients on loop diuretics with borderline renal function, it introduces a risk of orthostatic hypotension, dehydration, and acute kidney injury.

The FDA label recommends assessing volume status before initiation and monitoring renal function in patients susceptible to volume contraction 6. This concern is not theoretical. In DAPA-HF, volume depletion events occurred in 7.5% of the dapagliflozin arm versus 6.8% on placebo 1.

Tresiba has no meaningful effect on blood pressure or fluid balance. It does not interact with renal sodium handling. For patients prone to dehydration or those on multiple antihypertensives, this neutrality can be an advantage.

Fournier Gangrene and Rare but Serious Events

In 2018, the FDA issued a warning about Fournier gangrene (necrotizing fasciitis of the perineum) associated with the entire SGLT2 inhibitor class, including dapagliflozin 6. Between 2013 and 2019, approximately 55 confirmed cases were identified across all SGLT2 inhibitors in the FAERS database. Given that millions of patients have used these drugs, the absolute risk is extremely low, but the condition carries 20%, 40% mortality when it occurs.

Tresiba's rare serious events include severe hypoglycemia (which can cause seizures, loss of consciousness, or death) and, with chronic use, injection-site amyloidosis 5. A 2022 review in The Lancet Diabetes & Endocrinology documented that insulin-derived amyloidosis at injection sites can impair absorption and lead to erratic glycemic control 9.

Who Should Get Which Drug (and When Both)

These drugs are not interchangeable. They occupy different rungs of the ADA treatment algorithm, and many patients end up taking both.

A patient with type 2 diabetes, an eGFR above 25 mL/min, and established atherosclerotic cardiovascular disease or heart failure should receive an SGLT2 inhibitor (such as dapagliflozin) regardless of A1c, according to the 2024 ADA consensus pathway 4. If that same patient cannot reach glycemic targets on oral agents and a GLP-1 RA, adding basal insulin (such as degludec) is the next step. At that point, Farxiga and Tresiba are used together, not in competition.

The Endocrine Society's 2023 clinical practice guideline for type 2 diabetes management recommends: "SGLT2 inhibitors should be considered early in the treatment algorithm for patients with heart failure or CKD, independent of glycemic need" 10. This positions dapagliflozin as a cardiorenal drug first and a glucose-lowering drug second.

For patients with type 1 diabetes, the calculus is different. Tresiba is a cornerstone of basal-bolus therapy. Farxiga is not FDA-approved for type 1 diabetes due to elevated DKA risk.

Side-Effect Comparison Summary Table

Below is a consolidated comparison of the key adverse events for each drug, grounded in trial data and prescribing information.

Hypoglycemia (monotherapy): Farxiga, 0.1% major episodes; Tresiba, 4.9% severe episodes over 2 years in DEVOTE 2.

Genital mycotic infections: Farxiga, 4.8% women / 2.8% men; Tresiba, not increased versus background rate 3.

DKA: Farxiga, ~0.1% per patient-year (class-wide estimate); Tresiba, not applicable.

Weight change: Farxiga, −2 to −3 kg; Tresiba, +1 kg average.

Cardiovascular benefit: Farxiga, 26% reduction in HF hospitalization/CV death (DAPA-HF); Tresiba, MACE non-inferior to glargine (DEVOTE).

Volume depletion: Farxiga, 7.5% in DAPA-HF; Tresiba, neutral.

Injection-site reactions: Farxiga, none (oral drug); Tresiba, <2% with proper site rotation 5.

Patients starting dapagliflozin should receive counseling on genital hygiene, DKA warning signs (nausea, vomiting, abdominal pain, fruity breath), and the need to hold the drug before major surgery. Patients starting insulin degludec should receive education on hypoglycemia recognition and treatment, injection-site rotation, and sick-day insulin adjustment rules.